AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03252379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hepaticojejunostomy
Description: * Under general intubation anesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the CBD and prepare the unaffected proximal part for anastomosis. The Roux jejunal loop is prepared and passed retrocolic to reach the porta hepatis.~* Then, the hepaticojejunostomy is done via end to side anastomosis using interrupted sutures of polyglactin of 3-0 or 4-0 size. The anastomosis is done 10-15 cm away from the free distal end of the Roux jejunum loop to allow anastomosis without tension to the stomach. A biliary stent may be optionally placed according to operative circumstances and is brought out through the anterior abdominal wall.
Study NCT03252379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified hepaticojejunostomy with subcutaneous access loop
Description: In the subcutaneous access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.~The closed free end of roux loop is passed through the anterior abdominal wall in the right subcostal area and then fixed to the wall in a subcutaneous position using 3/0 polyglactin sutures. The limb between the hepaticojejunal anastomosis and the subcutaneous fixation should be short and straight.~Four Ligaclips are used to mark the jejunal loop by clipping the sutures holding the access loop in place.
Study NCT03252379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified hepaticojejunostomy with gastric access loop
Description: * In the gastric access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.The end of the Roux jejunal loop taken up for hepaticojejunostomy is not closed but is anastomosed to the anterior wall of the gastric antrum near the pyloric orifice.~* All the enterogastrostomies and enteroenterostomies were in the form of single-layer continuous sutures of polyglactin of 3-0 size. An intraperitoneal drain was left in the hepatorenal pouch before closing the incision.
Study NCT01683357 — intervention group
Intervention type: PROCEDURE
Intervention: Hepatectomy
Description: Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.~If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).~Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy.
Study NCT02392624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab 300 mg administered SC Q4W.
Study NCT02392624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omalizumab
Description: Omalizumab 300 mg administered SC Q4W.
Study NCT02392624 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to omalizumab administered SC Q4W.
Study NCT00936715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: 200/300 mg tablet administered orally once daily
Study NCT02518438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
Study NCT01868997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teprotumumab
Study NCT01868997 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study NCT03694886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Anhydrous with small sucrose pill
Description: caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 1 mm sucrose pillule
Study NCT03694886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - large sucrose pill
Description: sucrose pillules of 5 mm diameter will be given to all participants in the large pill groups
Study NCT03694886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Anhydrous with large sucrose pill
Description: caffeine anhydrous that has been weighed out to 90 mg per dose presented with a 5 mm sucrose pillule
Study NCT03694886 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - small sucrose pill
Description: sucrose pillules of 1 mm diameter will be given to all participants in the small pill groups
Study NCT01193244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Description: Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
Study NCT01193244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of \<50 ng/dL.
Study NCT01193244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
Study NCT01193244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of \<50 ng/dL.
Study NCT02263027 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine
Description: Licensed trivalent inactivated influenza vaccine
Study NCT02683577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telotristat etiprate
Study NCT03891381 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tetragraph quantitative monitoring
Description: Neuromuscular monitoring will be guided by information provided by the Tetragraph
Study NCT03891381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tetragraph quantitative monitoring
Description: Neuromuscular monitoring will be guided by information provided by the Tetragraph
Study NCT01601548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Cancer Recovery
Description: Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
Study NCT00716417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
Study NCT00716417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992
Description: low to high dose, daily
Study NCT04570137 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary fiber supplementation
Description: 1. 16g/day: mix of 70% wheat-bran arabinoxylan and 30% oat-derived fiber (ß-glucan)~2. 16g/day: mix of 50% inulin and 50% oligofructose from chicory
Study NCT00707889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-869
Description: 12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
Study NCT00707889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 10 mg/kg QD, IV on Day 1 of each 14-day cycle
Study NCT00707889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: 85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
Study NCT00707889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folinic acid
Description: 400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
Study NCT00707889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: 400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
Study NCT00707889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-869
Description: 7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
Study NCT03420118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumour tissue collection
Description: Depending on the status of disease when participants join the study, a sample of tumour tissue may be collected from:~* A previous surgery for the disease,~* A biopsy for diagnosing the disease,~* Other surgical procedures done for clinical management or possible cancer related complications (e.g., bowel obstruction).~In addition:~* Patients undergoing pre-screening prior to diagnosis will have tumour sample collected at the time of surgery.~* At anytime participants require a biopsy as a part of their cancer care, a sample of that tumour tissue will be collected.~* New biopsies will be done to collect fresh tumour tissue each time participants' disease worsens.
Study NCT03420118 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood samples will be collected at the following different times points:~* All patient undergoing pre-screening for histological diagnosis will have blood samples collected.~* Before starting a new line of treatment for the disease,~* One week after starting a new line of treatment for the disease,~* During treatment, at each radiological assessment (imaging scan) that will be done to check the status of the disease,~* At the time the disease worsens or relapses (comes back)~* During observation/follow-up, at the time of any radiological assessments that will be done to check the status of the disease
Study NCT00068692 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Undergo external beam radiation therapy
Study NCT00068692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT00068692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT00068692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT00068692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT01790724 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking exercise
Study NCT01790724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking exercise
Study NCT02153320 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood Sampling
Description: Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
Study NCT02324192 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ultrasonography
Description: imaging findings
Study NCT03834181 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitoring evaluation by connected devices: Wristband activity tracker Garmin Vivosmart® 3, Fora® Scale 550, Terraillon® Tensioscreen, Pulse oximeter Nonin® 3230, thermometer Fora® IR20b
Description: All patients will be monitored before and after the bariatric surgery:~* During the preoperative preparation phase: weight, exercise, blood pressure and heart rate~* In the immediate post operative period: continuous monitoring of the heart rate with a telemetry system~* Prolonged follow-up: weight, exercise, blood pressure and heart rate
Study NCT01527097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
Study NCT01527097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin placebo
Description: Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
Study NCT02086253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-788 and/or BQ-123
Study NCT04216459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral lactobacillus probiotics plus intramuscular cholecalciferol
Description: According to leukocyte anti- sedimentation rate (LAR) result on day 1 patients will be classified into high risk for sepsis patients (LAR \< 15 %) and low risk for sepsis patients (LAR ≥ 15%) High risk sepsis patients will be randomly allocated into one of the 3 groups (sealed opaque envelops) to vitamin D plus probiotics intervention group (HR-DP) group. to vitamin C plus vitamin B intervention group (HR-CB) group. to control group (HR-C) group that does not receive any supplement
Study NCT04216459 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous vitamin C plus thiamine
Description: starting from day 1 in a dose of 1 gm vitamin C and 200 mg thiamine intravenous 4 times at 12-hour intervals for 48 hours
Study NCT03689153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: Single ascending IV low, middle, and high dose of JNJ-63733657 will be administered in sequential cohorts. The progression to the next (higher) dose level is dependent on acceptable safety and tolerability profile of JNJ-63733657 obtained after dose administration of the current dose level. The length of time between dosing days of cohorts will be at least 14 days.
Study NCT03689153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo intravenously.
Study NCT03970694 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Since 2006, neoadjuvant chemoradiotherapy has been a recommendation as standard treatment for locally advanced rectal cancer, and has been widely applied to clinical use. As for locally advanced colon cancer, it still lacks evidence to support whether neoadjuvant chemoradiotherapy is a beneficial option.We recently reported clinical data about therapeutic effect of 60 unresectable locally advanced colon cancer cases and it was exciting. According to our results, through neoadjuvant chemoradiotherapy, R0 resection rate is 86%, local recurrence rate is 10.2%, 3-year OS and 5-year OS are 76.7% and 66.6%, respectively.Colorectal cancer diagnoses and treatment guidelines written by Chinses Society of Clinical Oncology (ver. 2017, 2018), suggested that neoadjuvant chemoradiotherapy was an optional treatment strategy or secondary recommended treatment strategy.
Study NCT03970694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin+capecitabine
Description: Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
Study NCT03970694 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oxaliplatin+capecitabine
Description: Colorectal cancer is one of the most common malignant tumors, the morbidity and mortality rate are both in rising trend. 10-23% newly diagnosed colon cancer is at locally advanced stage and surgical unresectable. For this subgroup, treatment guidelines recommend neoadjuvant chemotherapy with or without targeted therapy.
Study NCT01309542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine Succinate
Description: Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
Study NCT01974492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper leg vein harvesting
Description: Patients whose saphenous veins are harvested from upper legs.
Study NCT01974492 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower leg vein harvesting
Description: Patients whose saphenous veins are harvested from lower legs.
Study NCT02613650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162 and mFOLFIRI
Description: MEK162 in combination with mFOLFIRI in a 14 day cycle~MEK162 will be given single agent 6 day lead in and then will be given in combination with mFOLFIRI~mFOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)~Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle~Level -1: mFOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: mFOLFIRI + MEK162 30 mg twice daily Level 2: mFOLFIRI + MEK162 45 mg twice daily
Study NCT04424160 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP injection in the endometrium
Description: Within 5 days after the cessation of menstrual period, endometrial PRP procedure will be planned. Approximately 20 ml of blood sample will be collected under sterile conditions, and PRP will be prepared. The same day, within 2 hours of sample preparation, PRP injection will be performed transvaginally under ultrasound guidance and under sedation anesthesia into the endometrial region of the endometrium in several positions.On the same day after the procedure, the patient will be observed in the outpatient room and will be discharged on the same day.
Study NCT00809666 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Automated blood pressure recording device Omron HEM 705CP
Description: All subsequent blood pressure recordings done using the automated device
Study NCT02628236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid (ALA)
Description: 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
Study NCT02628236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLU-U
Description: 10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
Study NCT01912742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Very-low calorie diet (VLCD)
Study NCT01912742 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low calorie diet (LCD)
Study NCT03545763 — intervention group
Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
Study NCT03107520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative contrast-enhanced ultrasound (CEUS)
Description: An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
Study NCT03107520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumason
Description: Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
Study NCT04609228 — intervention group
Intervention type: OTHER
Intervention: Non-acceptance of blood-transfusions
Description: Patients who do not accept blood products transfusions
Study NCT04609228 — intervention group
Intervention type: OTHER
Intervention: Acceptance of blood-transfusions
Description: Patients who accept blood products transfusions
Study NCT04056572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139
Description: TQ-B3139 is competitive multi-target protein kinase inhibitor of Met/ALK/ROS.
Study NCT00840086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
Study NCT01845012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily hemodialysis at low dialysate flow
Description: Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
Study NCT00833053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
Study NCT00833053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab and methotrexate
Description: Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
Study NCT04425291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4-valent HPV Vaccine
Description: Subjects received 3 doses of 4-valent HPV vaccine according to a 0, 2, 6-month schedule.
Study NCT04425291 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV Vaccine
Description: Subjects received 3 doses of 9-valent HPV vaccine according to a 0, 2, 6-month schedule.